Differential EphA2 epitope display on normal versus malignant cells.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 14633720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer

  2004cited by this paper
• Differential regulation of EphA2 in normal and malignant cells.

  2003cited by this paper
• Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.

  2003cited by this paper
• EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma

  2003cited by this paper
• EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma

  2003cited by this paper
• c-Cbl-dependent EphA2 protein degradation is induced by ligand binding.

  2002cited by this paper
• Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.

  2002cited by this paper
• Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis

  2002cited by this paper
• EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

  2001cited by this paper
• MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer.

  2001cited by this paper
• Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).

  2001cited by this paper
• The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization

  2000cited by this paper
• Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation

  2000cited by this paper
• E-cadherin regulates the function of the EphA2 receptor tyrosine kinase.

  1999cited by this paper
• Overexpression of the EphA2 tyrosine kinase in prostate cancer

  1999cited by this paper
• Expression of E-cadherin and catenins in invasive mammary carcinomas.

  1997cited by this paper
• E-cadherin engagement stimulates tyrosine phosphorylation.

  1997cited by this paper
• Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis

  1995cited by this paper
• Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity.

  1994cited by this paper
• Adhesion molecules in tumor metastasis.

  1993cited by this paper
• cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases

  1990cited by this paper

• A novel bicyclic peptide-drug conjugate of 3-fluoro-10-hydroxy-evodiamine for targeted colorectal cancer therapy.

  2026cites this paper
• Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody.

  2025cites this paper
• Computational design of synthetic receptors with programmable signalling activity for enhanced cancer T cell therapy.

  2025cites this paper
• Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions.

  2025cites this paper
• Integrative bioinformatics and drug repurposing for metastatic prostate cancer: identifying novel therapeutic targets by transcriptional profiling and molecular Modeling.

  2025cites this paper
• Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications

  2025cites this paper
• Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR

  2025cites this paper
• Ephrin A1 ligand‐based CAR‐T cells for immunotherapy of EphA2‐positive cancer

  2025cites this paper
• Targeting the EphA2 pathway: could it be the way for bone sarcomas?

  2024cites this paper
• EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities

  2024cites this paper
• Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment

  2024cites this paper
• Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors

  2023cites this paper
• Development of an Anti-EphB4 Monoclonal Antibody for Multiple Applications Against Breast Cancers

  2023cites this paper
• Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

  2023cites this paper
• Strategies to overcome the side effects of chimeric antigen receptor T cell therapy

  2022cites this paper
• A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy

  2022cites this paper
• Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas

  2021cites this paper
• Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

  2021cites this paper
• EphA2: A promising therapeutic target in breast cancer.

  2021cites this paper
• Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates

  2021cites this paper
• Lithocholic Acid-Tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of Niclosamide to prostate cancer via EphA2 receptor.

  2021cites this paper
• Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents

  2020cites this paper
• Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin

  2020cites this paper
• The EphA2 and cancer connection: potential for immune-based interventions

  2020influential citation
• Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours

  2020cites this paper
• Targeting EphA2 in cancer

  2020cites this paper
• Identification of key genes and their functions in palbociclib-resistant breast carcinoma by using bioinformatics analysis

  2020cites this paper
• Antibody Targeting of Eph Receptors in Cancer

  2020influential citation
• Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

  2019cites this paper
• Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

  2018cites this paper
• Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy

  2018cites this paper
• Dysregulated erythropoietin-producing hepatocellular receptor A2 (EphA2) is involved in tubal pregnancy via regulating cell adhesion of the Fallopian tube epithelial cells

  2018cites this paper
• Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate

  2018cites this paper
• Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies

  2018cites this paper
• CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

  2018cites this paper
• A T-cell engager-armed oncolytic vaccinia virus to target the tumor stroma

  2017cites this paper
• PET-Guided Evaluation and Optimization of Internalized Antibody–Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor

  2017cites this paper
• Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling

  2017cites this paper
• Eph RECEPTORS AS A TARGET TO DEVELOP NOVEL THERAPIES TO CONTROL NEURODEGENERATION AND NEUROPATHIC DISEASES

  2017cites this paper
• Molecular and functional crosstalk between extracellular Hsp 90 and ephrin A 1 signaling

  2017cites this paper
• ANTIBODES THAT BIND TO EPHB4

  2017cites this paper
• The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

  2017cites this paper
• When chemical proteomics meets medicinal chemistry: Guided drug discovery towards EPHA2 inhibitors

  2017cites this paper
• Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

  2017cites this paper
• Role of Growth Factor Signaling in Cancer

  2016cites this paper
• Ephrin and Eph-receptor growth factor signaling in non small cell lung cancer : identification of biomarkers and therapeutic targets

  2016cites this paper
• Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous‐cell carcinoma

  2015cites this paper
• CAR T-cell therapy: toxicity and the relevance of preclinical models.

  2015cites this paper
• Eph receptors and ephrins: therapeutic opportunities.

  2015cites this paper
• Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer

  2015cites this paper
• Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond.

  2015cites this paper
• Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2

  2015cites this paper
• Exploring the role of Vδ1+ γδ T cells in immune stress surveillance

  2015cites this paper
• EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells

  2014cites this paper
• Spatial control of membrane receptor function using ligand nanocalipers

  2014cites this paper
• Therapeutic perspectives of Eph-ephrin system modulation.

  2014cites this paper
• CAR T Cells for Solid Tumors: Armed and Ready to Go?

  2014cites this paper
• Inhibiting Eph kinase activity may not be “Eph”ective for cancer treatment

  2014cites this paper
• Design, Synthesis and Bioevaluation of an EphA2 Receptor‐Based Targeted Delivery System

  2014cites this paper
• Prognostic role of EphA2 in various human carcinomas: a meta-analysis of 23 related studies

  2014cites this paper
• T cells redirected to EphA2 for the immunotherapy of glioblastoma.

  2013cites this paper
• Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.

  2012cites this paper
• Eph receptors and ephrins as targets for cancer therapy

  2012cites this paper
• Cancer Therapy : Preclinical Targeted Delivery of Paclitaxel to EphA 2-Expressing Cancer Cells

  2012cites this paper
• Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases.

  2012cites this paper
• Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells

  2012cites this paper
• Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

  2012cites this paper
• Selective targeting of cancer cells with RNA aptamers

  2012influential citation
• EphrinA1–EphA2 interaction‐mediated apoptosis and FMS‐like tyrosine kinase 3 receptor ligand‐induced immunotherapy inhibit tumor growth in a breast cancer mouse model

  2012cites this paper
• Investigating immune recognition of an epithelial stress antigen by Human gamma delta T cells AND Investigation into the chemokine profile of Ag-specific T cell responses in Multiple Myeloma and MGUS patients compared to age-matched controls.

  2012cites this paper
• INTEGRATION OF HSP90 INHIBITION IN COMBINATIONAL IMMUNOTHERAPIES TARGETING RECEPTOR TYROSINE KINASE EPHA2

  2012cites this paper
• EphA2-dependent molecular targeting therapy for malignant tumors.

  2011cites this paper
• Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

  2011cites this paper
• Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody.

  2011cites this paper
• Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation

  2011cites this paper
• Emerging strategies for EphA2 receptor targeting for cancer therapeutics

  2011cites this paper
• p53 and Angiogenesis

  2010cites this paper
• Eph receptors and ephrins in cancer: bidirectional signalling and beyond

  2010cites this paper
• Antibody–Cytotoxic Compound Conjugates for Oncology

  2010cites this paper
• Structure-activity relationship analysis of peptides targeting the EphA2 receptor.

  2010cites this paper
• Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis

  2010cites this paper
• EphA2: A Novel Target in Renal Cell Carcinoma

  2009cites this paper
• Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin Enhances EphA 2 + Tumor Cell Recognition by Specific CD 8 + T Cells

  2009cites this paper
• Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

  2009cites this paper
• Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

  2009influential citation
• DEVELOPING COMBINATIONAL IMMUNOTHERAPIES TARGETING TUMOR RECEPTOR TYROSINE KINASES

  2009influential citation
• Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1

  2008cites this paper
• Ephrin-A1 promotes the malignant progression of intestinal tumors in Apcmin/+ mice

  2008cites this paper
• Anticorps anti-epha2

  2008cites this paper
• Eph receptors in breast cancer: roles in tumor promotion and tumor suppression

  2008cites this paper
• Enhancement in Specific CD 8 T Cell Recognition of EphA 2 Tumors In Vitro and In Vivo after Treatment with Ligand Agonists 1

  2008cites this paper
• A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

  2008cites this paper
• Eph/ephrin signalling and function in oncogenesis: lessons from embryonic development.

  2008cites this paper
• The role of EphA2 RTK in breast cancer cell malignancy and tumor angiogenesis.

  2008cites this paper
• Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome

  2007cites this paper
• Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.

  2007cites this paper
• Assessing the potential of immunohistochemistry for systematic gene expression profiling.

  2007cites this paper
• Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

  2007cites this paper
• Affinitätsoptimierte epha2-agonistische antikörper und verfahren zu deren verwendung

  2006cites this paper
• Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth.

  2006influential citation